Operative Protocol for Testing the Efficacy of Nasal Filters in Preventing Airborne Transmission of SARS-CoV-2.
SARS-CoV-2 airborne transmission
bio-gel AgNP filters
endonasal filters
viral filtration efficacy protocol
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
23 10 2022
23 10 2022
Historique:
received:
19
09
2022
revised:
18
10
2022
accepted:
19
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
15
11
2022
Statut:
epublish
Résumé
Standardized methods for testing Viral Filtration Efficiency (VFE) of tissues and devices are lacking and few studies are available on aerosolizing, sampling and assessing infectivity of SARS-CoV-2 in controlled laboratory settings. NanoAg-coated endonasal filters appear a promising aid for lowering viable virus inhalation in both adult and younger populations (e.g., adolescents). to provide an adequate method for testing SARS-CoV-2 bioaerosol VFE of bio-gel Ag nanoparticles endonasal filters, by a model system, assessing residual infectivity as cytopathic effect and viral proliferation on in vitro cell cultures. A SARS-CoV-2 aerosol transmission chamber fed by a BLAM aerosol generator produces challenges (from very high viral loads (10 Each experimental setting is replicated three times and basic statistics are calculated. Efficiency of aerosolization is determined as difference between viral load in the nebulizer and in the Biosampler at the first day of experiment. Efficiency of virus filtration is calculated as RNA viral load ratio in collected bioaerosol with and without endonasal filters at the day of the experiment. Presence of infectious virus is assessed by plaque forming unit assay and RNA viral load variations. A procedure and apparatus for assessing SARS-CoV-2 VFE for endonasal filters is proposed. The apparatus can be implemented for more sophisticated studies on contaminated aerosols.
Sections du résumé
BACKGROUND
Standardized methods for testing Viral Filtration Efficiency (VFE) of tissues and devices are lacking and few studies are available on aerosolizing, sampling and assessing infectivity of SARS-CoV-2 in controlled laboratory settings. NanoAg-coated endonasal filters appear a promising aid for lowering viable virus inhalation in both adult and younger populations (e.g., adolescents).
OBJECTIVE
to provide an adequate method for testing SARS-CoV-2 bioaerosol VFE of bio-gel Ag nanoparticles endonasal filters, by a model system, assessing residual infectivity as cytopathic effect and viral proliferation on in vitro cell cultures.
METHODS
A SARS-CoV-2 aerosol transmission chamber fed by a BLAM aerosol generator produces challenges (from very high viral loads (10
RESULTS
Each experimental setting is replicated three times and basic statistics are calculated. Efficiency of aerosolization is determined as difference between viral load in the nebulizer and in the Biosampler at the first day of experiment. Efficiency of virus filtration is calculated as RNA viral load ratio in collected bioaerosol with and without endonasal filters at the day of the experiment. Presence of infectious virus is assessed by plaque forming unit assay and RNA viral load variations.
CONCLUSIONS
A procedure and apparatus for assessing SARS-CoV-2 VFE for endonasal filters is proposed. The apparatus can be implemented for more sophisticated studies on contaminated aerosols.
Identifiants
pubmed: 36360670
pii: ijerph192113790
doi: 10.3390/ijerph192113790
pmc: PMC9654745
pii:
doi:
Substances chimiques
Silver
3M4G523W1G
RNA
63231-63-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Curr Protoc Microbiol. 2020 Jun;57(1):ecpmc105
pubmed: 32475066
Expert Rev Med Devices. 2020 Dec;17(12):1265-1276
pubmed: 33203245
Adv Colloid Interface Sci. 2021 Jun;292:102435
pubmed: 33971389
Lancet Infect Dis. 2020 Apr;20(4):411-412
pubmed: 32105638
New Microbiol. 2017 Jul;40(3):155-160
pubmed: 28675243
Pathogens. 2020 Sep 17;9(9):
pubmed: 32957638
Emerg Infect Dis. 2022 Aug;28(7):1515-1517
pubmed: 35550234
Environ Health Perspect. 2021 Apr;129(4):47002
pubmed: 33793301
Nanomaterials (Basel). 2020 Aug 09;10(8):
pubmed: 32784939
J Biophotonics. 2021 Apr;14(4):e202000496
pubmed: 33619888
Nature. 2022 Mar;603(7902):715-720
pubmed: 35104836
J Hazard Mater. 2020 Sep 5;396:122640
pubmed: 32339873
Cell Host Microbe. 2022 Aug 10;30(8):1093-1102.e3
pubmed: 35526534
J Thorac Dis. 2018 Mar;10(3):2059-2069
pubmed: 29707364
Saf Sci. 2021 Jan;133:104995
pubmed: 32982065
Int J Environ Res Public Health. 2021 Aug 26;18(17):
pubmed: 34501610
mSphere. 2020 Oct 21;5(5):
pubmed: 33087517
Build Environ. 2022 Aug 1;221:109328
pubmed: 35784591
Build Environ. 2022 Feb 15;210:108728
pubmed: 34975206
Environ Res. 2021 Jul;198:111200
pubmed: 33901446
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Int J Environ Res Public Health. 2021 Oct 24;18(21):
pubmed: 34769691
Aerosol Sci Technol. 2020;54(5):496-519
pubmed: 35923417
Nature. 2022 Mar;603(7902):700-705
pubmed: 35104835
Microb Pathog. 2022 Mar;164:105442
pubmed: 35151823
Cell Rep Med. 2022 Feb 21;3(3):100556
pubmed: 35474742
Signal Transduct Target Ther. 2022 May 7;7(1):151
pubmed: 35525870
Eur Ann Allergy Clin Immunol. 2012 Apr;44(2):83-5
pubmed: 22768728